Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants.

Author: Bin TU ¹ ; Huiyuan WANG ¹ ; Xinran AN ¹ ; Jingkun QU ¹ ; Qianqian LI ¹ ; Yanrong GAO ¹ ; Mingjie SHI ¹ ; Hong QIU ¹ ; Yongzhuo HUANG ¹
Author Information

1. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Publication Type:Journal Article
Keywords: Delta variant; Heparan sulfate; Heparin nanoparticle; Pulmonary delivery; SARS-CoV-2; Spike protein
From: Acta Pharmaceutica Sinica B 2022;12(7):3187-3194
CountryChina
Language:English
Abstract: The heparin polysaccharide nanoparticles block the interaction between heparan sulfate/S protein and inhibit the infection of both wild-type SARS-CoV-2 pseudovirus and the mutated strains through pulmonary delivery.Image 1.